Human Genome Sciences reject $2.6 billion bid
Human Genome Sciences has rejected a $2.6 billion procurement bid from GlaxoSmithKline as they deemed it was not enough.
That crazy, fascinating sometimes incomprehensible world that lives at the intersection of biotechnology and intellectual property got quite a jolt last week when, in a court filing, the United States Justice Department opined that genes should not be eligible for patents.